These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27558311)

  • 1. Socioeconomic disadvantage but not remoteness affects short-term survival in prostate cancer: A population-based study using competing risks.
    Thomas AA; Pearce A; Sharp L; Gardiner RA; Chambers S; Aitken J; Molcho M; Baade P
    Asia Pac J Clin Oncol; 2017 Apr; 13(2):e31-e40. PubMed ID: 27558311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in impact of Aboriginal and Torres Strait Islander status on cancer stage and survival by level of socio-economic disadvantage and remoteness of residence-A population-based cohort study in Australia.
    Tervonen HE; Aranda S; Roder D; Walton R; Baker D; You H; Currow D
    Cancer Epidemiol; 2016 Apr; 41():132-8. PubMed ID: 26953842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
    Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
    Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multilevel determinants of breast cancer survival: association with geographic remoteness and area-level socioeconomic disadvantage.
    Dasgupta P; Baade PD; Aitken JF; Turrell G
    Breast Cancer Res Treat; 2012 Apr; 132(2):701-10. PubMed ID: 22160639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rural residency and prostate cancer specific mortality: results from the Victorian Radical Prostatectomy Register.
    Papa N; Lawrentschuk N; Muller D; MacInnis R; Ta A; Severi G; Millar J; Syme R; Giles G; Bolton D
    Aust N Z J Public Health; 2014 Oct; 38(5):449-54. PubMed ID: 24962513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of geographic unit of analysis on socioeconomic inequalities in cancer survival and distant summary stage - a population-based study.
    Tervonen HE; Morrell S; Aranda S; Roder D; You H; Niyonsenga T; Walton R; Baker D; Currow D
    Aust N Z J Public Health; 2017 Apr; 41(2):130-136. PubMed ID: 27960223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
    Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
    Aizer AA; Chen MH; Hattangadi J; D'Amico AV
    BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry.
    Bolton DM; Papa N; Ta AD; Millar J; Davidson AJ; Pedersen J; Syme R; Patel MI; Giles GG
    BJU Int; 2015 Oct; 116 Suppl 3():66-72. PubMed ID: 26176738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
    Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
    Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic variation in prostate cancer survival in New South Wales.
    Yu XQ; Luo Q; Smith DP; O'Connell DL; Baade PD
    Med J Aust; 2014 Jun; 200(10):586-90. PubMed ID: 24882490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Social connectedness and mortality after prostate cancer diagnosis: A prospective cohort study.
    Wu Z; Nguyen NH; Wang D; Lynch BM; Hodge AM; Bassett JK; White VM; Borland R; English DR; Milne RL; Giles GG; Dugué PA
    Int J Cancer; 2020 Aug; 147(3):766-776. PubMed ID: 31721182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer survival disparities worsening by socio-economic disadvantage over the last 3 decades in new South Wales, Australia.
    Tervonen HE; Aranda S; Roder D; You H; Walton R; Morrell S; Baker D; Currow DC
    BMC Public Health; 2017 Sep; 17(1):691. PubMed ID: 28903750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating variation in use of definitive therapy and risk-adjusted prostate cancer mortality in England and the USA.
    Sachdeva A; van der Meulen JH; Emberton M; Cathcart PJ
    BMJ Open; 2015 Feb; 5(2):e006805. PubMed ID: 25712821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
    BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.